Celon Pharma

Celon Pharma EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Celon Pharma (CLN.WA) as of Oct 24, 2026 is -41.19. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -35.76 — a change of 15.17% (lower).

EV/FCF

-41.19

YoY

15.17%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Celon Pharma is 2025 -41.19 . EV/FCF (Enterprise Value to Free Cash Flow) of Celon Pharma was 2024 -35.76 . It decreases by 15.17% lower compared to the previous year.

The Celon Pharma EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-28.38 PLN
Jan 1, 2019
-17.07 PLN
Jan 1, 2020
-43.94 PLN
Jan 1, 2021
402.93 PLN
Jan 1, 2022
-29.07 PLN
Jan 1, 2023
-28.48 PLN
Jan 1, 2024
-35.76 PLN
Jan 1, 2025
-41.19 PLN
The Celon Pharma EV/FCF history
YEAREV/FCFYoY
-41.19+15.17%
-35.76+25.58%
-28.48-2.04%
-29.07-107.22%
402.93-1,016.96%
-43.94+157.36%
-17.07-39.85%
-28.38-83.87%
-175.99-89.20%
-1,629.24-1,062.95%
169.19-75.76%
698.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celon Pharma Stock analysis

What does Celon Pharma do? Celon Pharma SA develops and manufactures generic drugs for cancer, neurological diseases, diabetes, and metabolic disorders. Its product portfolio includes pills like Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder Salmex. The company operates through its research center focused on oncology, neurology, and inflammatory and metabolic diseases. As a subsidiary of Glatton sp z o o, Celon Pharma SA serves healthcare providers and patients seeking affordable treatment options for chronic conditions. Celon Pharma SA's revenue comes from selling its generic drug portfolio to pharmacies, hospitals, and healthcare institutions. The firm's products target patients with conditions such as cancer, neurological disorders, and diabetes, where cost-effective alternatives are in demand. Glatton sp z o o, the parent company, likely oversees strategic direction and resource allocation for Celon Pharma SA's operations. The company's focus on generic drugs positions it within the pharmaceutical market segment for affordable treatments. Its research center develops new formulations within therapeutic areas like oncology and neurology, supporting ongoing product innovation. Celon Pharma SA's product lineup, including inhalation powder Salmex and pill-based treatments, caters to specific medical needs across multiple disease categories. Celon Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celon Pharma stock

EV/FCF (Enterprise Value to Free Cash Flow) of Celon Pharma is -41.19 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Celon Pharma changed from -35.76 to -41.19, representing a 15.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Celon Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Celon Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Celon Pharma

All Key Metrics — Celon Pharma